way-362450 and Atherosclerosis

way-362450 has been researched along with Atherosclerosis* in 1 studies

Other Studies

1 other study(ies) available for way-362450 and Atherosclerosis

Article	Year
Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). Journal of medicinal chemistry, 2009, Feb-26, Volume: 52, Issue:4 Azepino[4,5-b]indoles have been identified as potent agonists of the farnesoid X receptor (FXR). In vitro and in vivo optimization has led to the discovery of 6m (XL335, WAY-362450) as a potent, selective, and orally bioavailable FXR agonist (EC(50) = 4 nM, Eff = 149%). Oral administration of 6m to LDLR(-/-) mice results in lowering of cholesterol and triglycerides. Chronic administration in an atherosclerosis model results in significant reduction in aortic arch lesions. Topics: Administration, Oral; Animals; Aorta, Thoracic; Atherosclerosis; Azepines; Cholesterol; Disease Models, Animal; DNA-Binding Proteins; Drug Discovery; Indoles; Mice; Mice, Knockout; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Transcription Factors; Triglycerides	2009

Article

Year

Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR).

Journal of medicinal chemistry, 2009, Feb-26, Volume: 52, Issue:4

Azepino[4,5-b]indoles have been identified as potent agonists of the farnesoid X receptor (FXR). In vitro and in vivo optimization has led to the discovery of 6m (XL335, WAY-362450) as a potent, selective, and orally bioavailable FXR agonist (EC(50) = 4 nM, Eff = 149%). Oral administration of 6m to LDLR(-/-) mice results in lowering of cholesterol and triglycerides. Chronic administration in an atherosclerosis model results in significant reduction in aortic arch lesions.

Topics: Administration, Oral; Animals; Aorta, Thoracic; Atherosclerosis; Azepines; Cholesterol; Disease Models, Animal; DNA-Binding Proteins; Drug Discovery; Indoles; Mice; Mice, Knockout; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Transcription Factors; Triglycerides

2009